List view / Grid view
Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to antibody therapies for COVID-19. Antibody cocktails targeting the S protein receptor binding domain (RBD) are one way to avoid viral neutralisation escape, however only certain antibody combinations are currently effective.…
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
AbCellera and Eli Lilly have announced their partnership to develop, manufacture and distribute antibody treatments for the COVID-19 coronavirus.
BenevolentAI is the first AI company to have a CMO on its staff.
28 July 2016 | By Epidarex Capital
Epidarex Capital announces the launch of Nodthera Limited, a new biotech company focused on the discovery and development of novel inhibitors of the NLRP3 inflammasome...
10 June 2016 | By Victoria White, Digital Content Producer
The grant will be used to build a registry that will contain clinical data to advance the research and discovery of new treatments for migraine...
3 November 2015 | By Victoria White
Adding 130,000 square feet to Lilly's existing complex, the new building will feature a multi-disciplinary laboratory that facilitates collaboration across multiple research functions...
13 October 2015 | By Victoria White
ImaginAb will conduct preclinical research using its immune imaging agent, IAB22M2C, to detect T-cell trafficking, redirection and infiltration in response to Lilly oncology molecules...
12 October 2015 | By Victoria White
As part of the expanded collaboration, Innovent could receive additional milestones totalling more than $1 billion if the products reach certain milestones...
12 October 2015 | By Victoria White
Lilly has announced plans to add 30,000 square feet to its research and development site at the Alexandria Centre for Life Science in New York...
6 August 2015 | By Synthesis and Solid State Pharmaceutical Centre (SSPC)
Read how the Synthesis and Solid State Pharmaceutical Centre (SSPC) is positioning Ireland as a global hub for advanced pharmaceutical manufacturing...
23 July 2015 | By Victoria White
Lilly has revealed plans to expand its Biotechnology Centre located in San Diego, effectively doubling the Company's research presence in the area...
29 June 2015 | By Victoria White
Immunocore and Lilly have entered into a collaboration to explore the utility of IMCgp100 in combination with galunisertib and merestinib in melanoma...
